18F-DCFPyL Uptake in an Incidentally Detected Follicular Lymphoma by PET/CT Performed for Biochemically Recurrent Prostate Cancer

被引：2

作者：

Meijer, Dennie ^{[1
]}

Wondergem, Maurits ^{[2
]}

Knol, Remco J. J. ^{[2
]}

Broos, Wouter A. M. ^{[2
]}

van der Zant, Friso M. ^{[2
]}

机构：

[1] Amsterdam Univ Med Ctr, Locat VU Med Ctr, Dept Urol, Amsterdam, Netherlands

[2] Noordwest Ziekenhuisgrp, Dept Nucl Med, Location Alkmaar, Alkmaar, Netherlands

来源：

CLINICAL NUCLEAR MEDICINE | 2020年 / 45卷 / 02期

关键词：

F-18-DCFPyL PET/CT; prostate cancer; follicular lymphoma; MEMBRANE ANTIGEN; EXPRESSION;

D O I：

10.1097/RLU.0000000000002738

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

A 75-year-old man, treated with curative intent for histopathologically proven prostate cancer (initial prostate-specific antigen, 27 ng/mL; Gleason 4 + 5 = 9) through external beam radiation therapy in 2010 in combination with 3 years of androgen deprivation therapy (leuprorelin), underwent F-18-DCFPyL PET/CT for biochemical recurrence with a prostate-specific antigen of 4.1 ng/mL in February 2019. Multiple pelvic and some para-aortic lymph nodes showed highly increased F-18-DCFPyL uptake, suspicious for metastases. Incidentally, a solid mesenteric mass and mesenteric lymph nodes with moderately increased F-18-DCFPyL uptake were found. Upon histopathological evaluation, this proved to be a low-grade follicular lymphoma.

引用

页码：E96 / E97

页数：2

共 12 条

[1]

Afshar-Oromieh A, 2013, EUR J NUCL MED MOL I, V40, P786

[2]

Chang SS, 1999, CANCER RES, V59, P3192

[3] 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer [J].

Chen, Ying ;

Pullambhatla, Mrudula ;

Foss, Catherine A. ;

Byun, Youngjoo ;

Nimmagadda, Sridhar ;

Senthamizhchelvan, Srinivasan ;

Sgouros, George ;

Mease, Ronnie C. ;

Pomper, Martin G. .

CLINICAL CANCER RESEARCH, 2011, 17 (24) :7645-7653

[4] Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT [J].

Kanthan, Gowri L. ;

Coyle, Luke ;

Kneebone, Andrew ;

Schembri, Geoffrey Paul ;

Hsiao, Edward .

CLINICAL NUCLEAR MEDICINE, 2016, 41 (06) :500-501

[5] Prostate specific antigen only progression of prostate cancer [J].

Moul, JW .

JOURNAL OF UROLOGY, 2000, 163 (06) :1632-1642

[6] Detection of Synchronous Primary Malignancies with 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients [J].

Osman, Medhat M. ;

Iravani, Amir ;

Hicks, Rodney J. ;

Hofman, Michael S. .

JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (12) :1938-1942

[7]

Perera M, 2019, BJU INT, V123, P45

[8] Prostate-specific membrane antigen expression as a predictor of prostate cancer progression [J].

Perner, Sven ;

Hofer, Matthias D. ;

Kim, Robert ;

Shah, Rajal B. ;

Li, Haojie ;

Moeller, Peter ;

Hautmann, Richard E. ;

Gschwend, Juergen E. ;

Kuefer, Rainer ;

Rubin, Mark A. .

HUMAN PATHOLOGY, 2007, 38 (05) :696-701

[9] Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference [J].

Roach, Mack, III ;

Hanks, Gerald ;

Thames, Howard, Jr. ;

Schellhammer, Paul ;

Shipley, William U. ;

Sokol, Gerald H. ;

Sandler, Howard .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (04) :965-974

[10] PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges [J].

Rowe, S. P. ;

Gorin, M. A. ;

Allaf, M. E. ;

Pienta, K. J. ;

Iran, P. T. ;

Pomper, M. G. ;

Ross, A. E. ;

Cho, S. Y. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (03) :223-230

← 1 2 →